Generic drug
Dabigatran etexilate price, strengths & recalls
Generic of Pradaxa
Pharmacies pay $24.01 for 30 capsules of Dabigatran etexilate 150 mg capsule this week, and from $21.46 to $26.88 across its 3 priced strengths and forms. 13 manufacturers make it. 9 recalls are ongoing. Its official label last changed on August 1, 2025.
9 open recallsGeneric- Fair cash price
- $38.11
- Strengths
- 3
- Makers
- 13
- Updated
- Nov 11
Dabigatran etexilate price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 75 mg capsule | $0.7152 | $21.46 / 30 capsules |
| 110 mg capsule | $0.8961 | $26.88 / 30 capsules |
| 150 mg capsule | $0.8005 | $24.01 / 30 capsules |
The lowest cost per capsule is 75 mg capsule at $0.7152. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of dabigatran etexilate
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 10 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Dabigatran etexilate
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use DABIGATRAN ETEXILATE CAPSULES safely and effectively. See full prescribing information for DABIGATRAN ETEXILATE CAPSULES. DABIGATRAN ETEXILATE capsules, for oral use Initial U.S. Approval: 2010
WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA
(A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS
Premature discontinuation of any oral anticoagulant, including dabigatran etexilate capsules, increases the risk of thrombotic events. If anticoagulation with dabigatran etexilate capsules is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant
[see Dosage and Administration (
2.6,
2.7,
2.8) and Warnings and Precautions (
5.1)].
(B) SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas may occur in patients treated with dabigatran etexilate capsules who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
• use of indwelling epidural catheters
• concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
• a history of traumatic or repeated epidural or spinal punctures
• a history of spinal deformity or spinal surgery
• optimal timing between the administration of dabigatran etexilate capsules and neuraxial procedures is not known
[see Warnings and Precautions (
5.3)].
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary
[see Warnings and Precautions (
5.3)].
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated
[see Warnings and Precautions (
5.3)].
WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS, and
(B) SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning
(A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including dabigatran etexilate capsules, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if dabigatran etexilate capsules are discontinued for a reason other than pathological bleeding or completion of a course of therapy (
2.6,
2.7,
2.8,
5.1).
(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated withdabigatran etexilate capsules who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis (
5.3). Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated (
5.3).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA022512 · Boehringer Ingelheim
- First approved
- October 19, 2010 (16 years ago)
- Latest approved change
- June 17, 2025
- Approved label
- PDF, Oct 3, 2025
- Generic makers
- 8 approved generic applications on the market
- Last patent listed
- July 20, 2031
Dabigatran etexilate questions
How much does dabigatran etexilate cost without insurance?
Pharmacies pay about $24.01 for 30 capsules of dabigatran etexilate 150 mg capsule ($0.8005 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $38.11. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of dabigatran etexilate?
Dabigatran etexilate is sold as Pradaxa. The generic has the same active ingredient and usually costs far less.
Is dabigatran etexilate in shortage?
No shortage is reported for dabigatran etexilate right now. We check the national shortage list every day.
Has dabigatran etexilate been recalled?
10 recalls on record, 9 ongoing. Recalls name specific lots - check yours.
When did the dabigatran etexilate label last change?
The official label was last updated on August 1, 2025 (version 8). See what changed.
Talk about dabigatran etexilate
No comments yet. Questions, tips, what worked for you - start the conversation.